Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score Journal Article

   

Authors:	Mariotti, V.; Page, D. B.; Davydov, O.; Hans, D.; Hudis, C. A.; Patil, S.; Kunte, S.; Girotra, M.; Farooki, A.; Fornier, M. N.
Article Title:	Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone score
Abstract:	Introduction Aromatase-inhibitors (AIs) are commonly used for treatment of patients with hormone-receptor positive breast carcinoma, and are known to induce bone density loss and increase the risk of fractures. The current standard-of-care screening tool for fracture risk is bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA). The fracture risk assessment tool (FRAX®) may be used in conjunction with BMD to identify additional osteopenic patients at risk of fracture who may benefit from a bone-modifying agent (BMA). The trabecular bone score (TBS), a novel method of measuring bone microarchitecture by DXA, has been shown to be an independent indicator of increased fracture risk. We report how the addition of TBS and FRAX®, respectively, to BMD contribute to identification of elevated fracture risk (EFR) in postmenopausal breast cancer patients treated with AIs. Methods 100 patients with early stage hormone-positive breast cancer treated with AIs, no prior BMAs, and with serial DXAs were identified. BMD and TBS were measured from DXA images before and following initiation of AIs, and FRAX® scores were calculated from review of clinical records. EFR was defined as either: BMD ≤−2.5 or BMD between −2.5 and −1 plus either increased risk by FRAX® or degraded microstructure by TBS. Results At baseline, BMD alone identified 4% of patients with EFR. The addition of FRAX® increased detection to 13%, whereas the combination of BMD, FRAX® and TBS identified 20% of patients with EFR. Following AIs, changes in TBS were independent of changes in BMD. On follow-up DXA, BMD alone detected an additional 1 patient at EFR (1%), whereas BMD+ FRAX® identified 3 additional patients (3%), and BMD+FRAX®+TBS identified 7 additional patients (7%). Conclusions The combination of FRAX®, TBS, and BMD maximized the identification of patients with EFR. TBS is a novel assessment that enhances the detection of patients who may benefit from BMAs. © 2016 The Authors
Keywords:	breast cancer; aromatase inhibitor; osteoporosis; osteopenia; adjuvant; fracture risk assessment tool; frax®; manitoba study; tbs; trabecular bone score
Journal Title:	Journal of Bone Oncology
Volume:	7
ISSN:	2212-1374
Publisher:	Elsevier Inc.
Date Published:	2017-06-01
Start Page:	32
End Page:	37
Language:	English
DOI:	10.1016/j.jbo.2016.10.004
PROVIDER:	scopus
PMCID:	PMC5469247
PUBMED:	28626628
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006802951&doi=10.1016%2fj.jbo.2016.10.004&partnerID=40&md5=0a4617a32f759ba4f53d0642a2ccd1d5
Notes:	Article -- Export Date: 3 July 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/112593